Stem cell-derived extracellular vesicles as a therapeutic for avascular necrosis: current status and future prospects

📖 Top 50% JournalSep 23, 2025Regenerative medicine

Stem cell particles as a treatment for bone tissue death without blood supply: current progress and future possibilities

AI simplified

Regenerative Health on OpenScience ↗PubMed ↗DOI ↗

Abstract

Extracellular vesicles (EVs) from stem cells may offer a safer and more cost-effective therapy for avascular necrosis (AVN).

Avascular necrosis (AVN) is a significant challenge in orthopedic practice requiring effective treatment strategies.
Current treatments include surgical options and non-surgical approaches like statin therapy and physiotherapy.
Regenerative therapies, including those using stem cell-derived extracellular vesicles, are being explored for AVN treatment.
Induced pluripotent stem cells (iPSCs) are promising for cell therapy, but their clinical use is limited by teratoma risk.
MSC-derived extracellular vesicles have shown therapeutic promise, while the use of iPSC-derived extracellular vesicles is slower due to high costs.

AI simplified

Avascular necrosis (AVN), also referred to as osteonecrosis (ON), is a major clinical challenge in orthopedic practice. Current treatment strategies include surgical options such as core decompression, as well as non-surgical approaches including statin therapy, weight reduction, and physiotherapy. Regenerative therapies - such as platelet-rich plasma injections, autologous bone marrow cell concentrates, and mesenchymal stem/stromal cells (MSCs), among others have shown some success. Although induced pluripotent stem cells (iPSCs) represent a promising source for cell therapy, their clinical application is restricted due to the risk of teratoma formation. In this context, the therapeutic potential of extracellular vesicles (EVs) secreted by stem cells has emerged as a relatively new area of investigation. This review summarizes findings from preclinical studies in animal models that have explored the use of MSC- and iPSC-derived EVs in the regenerative treatment of AVN/ON. Compared with MSC-EVs, the therapeutic use of iPSC-EVs has progressed more slowly, partly due to the high cost of expanding iPSCs to obtain a sufficient quantity of their EVs. Therefore, instead of using iPSC-derived EVs, the use of a cocktail of EVs secreted by iPSC-derived cellular derivatives may represent a safer, more cost-effective, and potentially more efficacious strategy for treating AVN.

Full Text

Full text is available at the source.

View full text ↗

Abstract

Full Text

Related papers